Busca avançada
Ano de início
Entree
(Referência obtida automaticamente do Web of Science, por meio da informação sobre o financiamento pela FAPESP e o número do processo correspondente, incluída na publicação pelos autores.)

Immunotherapy improves efficacy and safety of patients with HPV positive and negative head and neck cancer: A systematic review and meta-analysis

Texto completo
Autor(es):
Galvis, Marisol Miranda [1, 2] ; Borges, Gabriel Alvares [3, 2] ; de Oliveira, Thiago Bueno [4] ; de Toledo, Isabela Porto [3] ; Castilho, Rogerio Moraes [2, 5] ; Silva Guerra, Eliete Neves [3, 2] ; Kowalski, Luiz Paulo [6, 1, 7] ; Squarize, Cristiane Helena [2, 5]
Número total de Autores: 8
Afiliação do(s) autor(es):
[1] Univ Campinas UNICAMP, Piracicaba Dent Sch, Oral Diag Dept, Piracicaba - Brazil
[2] Univ Michigan, Sch Dent, Lab Epithelial Biol, Dept Periodont & Oral Med, 1011N Univ Ave, Ann Arbor, MI 48109 - USA
[3] Univ Brasilia, Hlth Sci Fac, Lab Oral Histopathol, Brasilia, DF - Brazil
[4] AC Camargo Canc Ctr, Clin Oncol Dept, Sao Paulo - Brazil
[5] Univ Michigan, Rogel Canc Ctr, Ann Arbor, MI 48109 - USA
[6] AC Camargo Canc Ctr, Dept Head & Neck Surg & Otorhinolaryngol, Sao Paulo - Brazil
[7] Univ Sao Paulo, Med Sch, Head & Neck Surg Dept, Sao Paulo - Brazil
Número total de Afiliações: 7
Tipo de documento: Artigo de Revisão
Fonte: CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY; v. 150, JUN 2020.
Citações Web of Science: 0
Resumo

Background: Despite multiple modalities used to management of head and neck squamous cell carcinoma (HNSCC), disease control remains unsatisfactory. Immunotherapy is emerging as a novel therapeutic approach. This systematic review assesses clinical data regarding immunotherapy efficacy and safety. Methods: Data from 11 clinical trials testing immunotherapy in HNSCC were assessed. We performed the meta-analysis to correlate the overall survival (OS), response rate (RR), adverse effects, HPV status, and PD-L1 expression. Results: Immunotherapy extended OS (hazard ratio = 0.77, p < 0.0001) and RR significantly (risk ratio = 1.41, p = 0.02). Patients with HPV-positive HNSCC exhibited a better RR (risk ratio = 1.29, p = 0.24) and OS (11.5 vs. 6.3 months). PD-L1 positive tumors showed a higher OS (9.9 vs. 6.5 months). Moreover, immunotherapy caused less adverse effects than standard therapy. Conclusion: Our results indicate the benefit of immunotherapy for improving RR and OS of HNSCC patients. The benefit is higher in patients with HPV and PD-L1 positive tumors. (AU)

Processo FAPESP: 16/03248-1 - Análise proteômica por espectrometria de massas do carcinoma de células escamosas oral em pacientes jovens
Beneficiário:Marisol Miranda Galvis
Linha de fomento: Bolsas no Brasil - Doutorado
Processo FAPESP: 17/16347-0 - Análise funcional de proteínas relacionadas ao HPV no carcinoma de células escamosas oral
Beneficiário:Marisol Miranda Galvis
Linha de fomento: Bolsas no Exterior - Estágio de Pesquisa - Doutorado